Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1993 1
1994 3
1995 2
1996 2
1997 1
1998 1
1999 3
2001 1
2002 2
2003 2
2004 1
2005 1
2009 1
2010 2
2011 1
2012 3
2013 10
2014 8
2015 11
2016 4
2017 10
2018 16
2019 13
2020 17
2021 25
2022 26
2023 20
2024 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Positionspapier „Universitäre Karrierewege“.
Staudacher JJ, Backes M, Bettinger D, Blüthner E, Dietz-Fricke C, Dugic A, Fusco S, Garbe J, Goeser F, Guliyeva S, Hamesch K, Hollenbach M, Huber Y, Kasper P, Kocheise L, Langsch P, Leppkes M, Martens N, Mücke MM, Munker S, Murillo K, Nagl S, Sanoubara F, Sturm N, Stathopoulos P, Storck K, Sulzer S, Thiel-Bodenstaff A, Tran F, Wiessner JR, Willuweit K, Yaqubi K, Zeidler C, Schlosser S; für die universitäre JuGa. Staudacher JJ, et al. Among authors: bettinger d. Z Gastroenterol. 2023 Aug;61(8):997-999. doi: 10.1055/a-2116-6308. Epub 2023 Aug 11. Z Gastroenterol. 2023. PMID: 37567237 German. No abstract available.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ. D'Alessio A, et al. Among authors: bettinger d. Hepatology. 2022 Oct;76(4):1000-1012. doi: 10.1002/hep.32468. Epub 2022 Apr 8. Hepatology. 2022. PMID: 35313048 Free PMC article.
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
Barsch M, Salié H, Schlaak AE, Zhang Z, Hess M, Mayer LS, Tauber C, Otto-Mora P, Ohtani T, Nilsson T, Wischer L, Winkler F, Manne S, Rech A, Schmitt-Graeff A, Bronsert P, Hofmann M, Neumann-Haefelin C, Boettler T, Fichtner-Feigl S, van Boemmel F, Berg T, Rimassa L, Di Tommaso L, Saeed A, D'Alessio A, Pinato DJ, Bettinger D, Binder H, John Wherry E, Schultheiss M, Thimme R, Bengsch B. Barsch M, et al. Among authors: bettinger d. J Hepatol. 2022 Aug;77(2):397-409. doi: 10.1016/j.jhep.2022.02.032. Epub 2022 Apr 1. J Hepatol. 2022. PMID: 35367533
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ. Fulgenzi CAM, et al. Among authors: bettinger d. Eur J Cancer. 2022 Nov;175:204-213. doi: 10.1016/j.ejca.2022.08.024. Epub 2022 Sep 20. Eur J Cancer. 2022. PMID: 36148739 Free article.
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.
Fulgenzi CAM, Scheiner B, D'Alessio A, Mehan A, Manfredi GF, Celsa C, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Pinter M, Sharma R, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Napolitano A, Vivaldi C, Salani F, Masi G, Silletta M, Lo Prinzi F, Di Giacomo E, Vincenzi B, Bettinger D, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Pirisi M, Park JW, Kudo M, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Ghittoni G, Cammà C, Stefanini B, Trevisani F, Giannini EG, Cortellini A, Pinato DJ. Fulgenzi CAM, et al. Among authors: bettinger d. JAMA Oncol. 2024 Sep 1;10(9):1253-1258. doi: 10.1001/jamaoncol.2024.2166. JAMA Oncol. 2024. PMID: 39023864
Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis.
Roehlen N, Stoehr F, Müller L, Luxenburger H, Gairing SJ, Reincke M, Schultheiss M, Berisha F, Weinmann A, Foerster F, Marquardt JU, Thimme R, Galle PR, Bettinger D, Kloeckner R. Roehlen N, et al. Among authors: bettinger d. Hepatol Commun. 2023 Sep 27;7(10):e0252. doi: 10.1097/HC9.0000000000000252. eCollection 2023 Oct 1. Hepatol Commun. 2023. PMID: 37756031 Free PMC article.
[Liver cirrhosis as a multisystem disease].
Bettinger D, Thimme R, Schultheiß M. Bettinger D, et al. Dtsch Med Wochenschr. 2024 Jun;149(12):690-695. doi: 10.1055/a-2146-7514. Epub 2024 May 23. Dtsch Med Wochenschr. 2024. PMID: 38781992 Review. German.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R. Vithayathil M, et al. Among authors: bettinger d. Hepatol Int. 2023 Aug;17(4):904-914. doi: 10.1007/s12072-023-10491-3. Epub 2023 Apr 1. Hepatol Int. 2023. PMID: 37005953 Free PMC article.
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.
Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D'Alessio A, Rimassa L, Pinato DJ, Ang C. Dharmapuri S, et al. Among authors: bettinger d. World J Gastrointest Oncol. 2023 Nov 15;15(11):1900-1912. doi: 10.4251/wjgo.v15.i11.1900. World J Gastrointest Oncol. 2023. PMID: 38077640 Free PMC article.
182 results